Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
May 18 2020 - 04:03PM
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon”
or the “Company”) today announced that it intends to offer and sell
shares of its common stock in an underwritten registered public
offering. All of the shares in the offering are to be sold by
Bellerophon. Bellerophon also intends to grant the underwriters a
30-day option to purchase up to an additional fifteen percent (15%)
of the number of shares of common stock offered in the public
offering at the public offering price, less underwriting
discounts and commissions. The offering is subject to market and
other conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
Bellerophon expects to use the net proceeds from this offering,
together with its existing cash and cash equivalents, for funding
its ongoing clinical trials, for working capital and general
corporate purposes.
Jefferies LLC is acting as the sole book-running manager for
this offering.
The securities are being offered pursuant to a shelf
registration statement on Form S-3, which was declared effective by
the Securities and Exchange Commission (the “SEC”)
on July 6, 2018. The offering will be made only by means of a
prospectus supplement and accompanying prospectus that form a part
of the registration statement. A preliminary prospectus supplement
relating to the offering will be filed with the SEC and
will be available on the SEC’s website at www.sec.gov. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
When available, copies of the preliminary prospectus supplement
and the accompanying prospectus relating to these securities may be
obtained for free from Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by telephone at +1 877 821
7388 or by email at Prospectus_Department@Jefferies.com.
About Bellerophon
Bellerophon is a clinical-stage biotherapeutics company
focused on developing innovative therapies that address significant
unmet medical needs in the treatment of cardiopulmonary diseases.
The Company is currently developing multiple product candidates
under its INOpulse® program, a proprietary pulsatile nitric oxide
delivery system.
Forward-looking Statements
Any statements in this press release about Bellerophon’s future
expectations, plans and prospects, including statements about the
timing, size, success and intended use of net proceeds of the
proposed offering as well as statements about the clinical
development of its product candidates, regulatory actions with
respect to the Company’s clinical trials and expectations regarding
the sufficiency of the Company’s cash balance to fund clinical
trials, operating expenses and capital expenditures, and other
statements containing the words “anticipate,” “believe,”
“continue,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “will,” “would,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: INOpulse® may
prove not to be an effective treatment for COVID-19 or approved for
marketing by the FDA, market and other conditions, the
uncertainties inherent in the initiation of future clinical trials,
availability and timing of data from ongoing and future clinical
trials and the results of such trials, whether preliminary or
interim results from a clinical trial will be predictive of the
final results of that trial or whether results of early clinical
trials will be indicative of the results of later clinical trials,
expectations for regulatory approvals, the FDA’s substantial
discretion in the approval process, availability of funding
sufficient for our foreseeable and unforeseeable operating expenses
and capital expenditure requirements and other factors discussed in
the “Risk Factors” section of the Company’s most recent Annual
Report on Form 10-K and in subsequent filings with the SEC. In
addition, any forward-looking statements included in this press
release represent Bellerophon’s views only as of the date of this
release and should not be relied upon as representing the Company’s
views as of any subsequent date. The Company specifically disclaims
any obligation to update any forward-looking statements included in
this press release, except as required by law.
Contacts
At
Bellerophon: |
|
At LifeSci Advisors: |
Fabian Tenenbaum, Chief Executive Officer |
|
Brian Ritchie |
(908) 574-4767 |
|
(212) 915-2578 |
Bellerophon Therapeutics (NASDAQ:BLPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bellerophon Therapeutics (NASDAQ:BLPH)
Historical Stock Chart
From Mar 2023 to Mar 2024